Download now: Gold and Silver Mining Stocks

Biotech Collaborates with Startup on Cancer Drug

Amgen (NASDAQ: AMGN) Drug to Target Tumors

Written by Swagato Chakravorty
Posted January 9, 2013

Amgen (NASDAQ: AMGN), the world’s leading biotech giant, will work with startup BIND Biosciences toward combining one of its kinase inhibitors with BIND’s nanotech vehicle, targeting tumors.

The deal provides BIND with a major source of funding for its in-development nanomedicine program.

FierceBiotech reports that the two companies hope to develop a kinase inhibitor featuring triple targeting, and BIND’s role will be to formulate Amgen’s kinase blocker within one of its tiny particles.

These can be used to target leaky tumor blood vessels specifically and thus aim directly for cancerous targets on malignant cells. Hence the triple attack—tumor tissue, cancerous cells, and kinases.

If it works, it’ll represent a major advance over preliminary steps taken by Novartis’ (NYSE: NVS) well-known Gleevec kinase inhibitor. Those early developments did target cancer at the molecular level, but also resulted in collateral impact to healthy cells

BIND’s highly specific approach minimizes the risk to healthy cells.

Amgen is already laying down quite a bit of funding as part of the deal, with another $46.5 million lying in wait, contingent on developmental milestones. BIND also stands to collect up to $134 million in regulatory and sales milestones.

Amgen, of course, would gain a highly promising addition to its portfolio of experimental cancer drugs, and the biotech would boost its lineup.

FierceBiotech quotes Scott Minick, BIND CEO:

"My feeling is that we've reached an inflection point," Minick said in an interview during the J.P. Morgan Healthcare Conference in San Francisco. "The pharma companies have all been looking at this technology, watching and tracking the data, but have not moved in a big way. I think you are seeing the beginning of what I hope and expect is a trend."

Since launching in 2007, BIND has raised about $76 million so far. It is backed by venture investors including ARCH Venture Partners, DHK Investments, Endeavour Vision, Flagship Ventures, Polaris Venture Partners, and Rusnano.

The official press release can be found here.


The Best Free Investment You'll Ever Make

Sign up for the free Wealth Daily e-letter below.

In each issue, you'll get our best investment research, designed to help you build a lifetime of wealth, minus the risk.


By signing up, you'll instantly receive our new report: Surviving the Coming Economic Collapse.... Finding The Most Profitable Investing Opportunities For Your Portfolio.
We Protect Your Privacy

Related Articles

2012 Biotech Boom
This year has been great for the biotech industry, but it may have been pushed by a slump in pharmaceutical companies.
Biotech of the Year
Regeneron Pharmaceuticals (NASDAQ: REGN) is recognized in the eighth-annual Biotechnology Company of the Year Awards...
Warren Buffett Bets on Biotech
Berkshire Hathaway (NYSE: BRK.A) is increasing its stake in DaVita Inc. (NYSE: DVA) against an increasing frequency of Diabetes in the U.S.


What is the benefit of the email subscription?
While the Wealth Daily website offers access to the articles and reports, as a newsletter subscriber you will be among the first to receive access to the valuable advice, delivered directly to your inbox daily, and you will have access to deals on our exclusive services.
Greece's Keynesian Experiment
Big Government Doesn't Work
China's World Domination
And Why it's Not Going to Happen
Should Greece Pay Its Debt?
The Case for a Greek Default
Gold's Early Warning
Deflation May Be Coming
How to Retire Like a King
5 Tips for a $1 Million Retirement
Guaranteed Returns in Cotton Futures!
Uncle Sam's $5 Billion Cotton Scam
Investing in Rhenium
More Valuable Than Oil and Gold Combined!
How to Retire Like a King
5 Tips for a $1 Million Retirement
Greece is Screwed!
10 Ways to Protect Yourself from the Global Economic Crisis
Investing in the Next Silver Bull Market
Silver Short Selling: Manipulation or Opportunity?